Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia

BACKGROUND: Nivestim™ (filgrastim) is a follow-on biologic agent licensed in the EU for the treatment of neutropenia and febrile neutropenia induced by myelosuppressive chemotherapy. Nivestim™ has been studied in phase 2 and 3 clinical trials where its efficacy and safety was found to be similar to...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamioner, Didier, Fruehauf, Stefan, Maloisel, Fréderic, Cals, Laurent, Lepretre, Stéphane, Berthou, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832750/
https://www.ncbi.nlm.nih.gov/pubmed/24237790
http://dx.doi.org/10.1186/1471-2407-13-547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832750/
https://www.ncbi.nlm.nih.gov/pubmed/24237790
http://dx.doi.org/10.1186/1471-2407-13-547

Ejemplares similares